TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Clinically meaningful improvements in pain and disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glucose production rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improvement in reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in P300 amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: decrease in N200 amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Student attitudes toward EBM
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-reported use of EBM in clinical practice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IPSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: SF-36 quality of life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Thirty-day survival free from myocardial infarction, pulmonary complications, renal failure, and stroke
Endpoint domain: Mortality/survival
Primary endpoint: One-year survival free from myocardial infarction, pulmonary complications, renal failure, and stroke
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with predefined adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Biopsy-proven rejection episodes grade >= 3A
Endpoint domain: Adverse events/effects
Primary endpoint: Mitogen-induced T lymphocyte activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom from progression
Endpoint domain: Mortality/survival
Primary endpoint: Freedom from late complications
Endpoint domain: Adverse events/effects
Primary endpoint: haemoglobin drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: requirement for blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: behavioral scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum treadmill walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treadmill intermittent claudication distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient-reported walking distance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: anesthetic costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in negative affect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in social affiliation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haemolysis (LDH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of MCPB system
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effectiveness of LiFE program compared to structured exercise program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hcy lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adequate anesthesia maintenance (BIS 40-60)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from discontinuation of propofol infusion to tracheal extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of tDCS and cognitive training on apathy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Probability of extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passing day 3 weaning assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for reintubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysmenorrhea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of life quality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bleaching effect on actinic lentigines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean reduction in MADRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate on the MADRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate (MADRS score < 10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased activation to food images in right medial prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increased activation in bilateral temporal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: Symptom remission
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ward evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Examination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-assessed knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participation in activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Neointimal index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in relationships with partners
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Odds of pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: Odds of live birth
Endpoint domain: Mortality/survival
Primary endpoint: Odds of multiple pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: daytime impairment (fatigue)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Overnight time-in-hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diet score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: healing rate of sinusitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventilation function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adhesions rate
Endpoint domain: Adverse events/effects
Primary endpoint: Mean of time of return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Regional sagittal angles (RSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMN (Mismatch Negativity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Genital HIV-1 RNA detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma HIV-1 RNA load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom from repeat revascularization procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Freedom from MACE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from induction to beginning of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hopelessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMV infection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CMV disease rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Active and passive range of motion (AROM and PROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: liver Dmean
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung Dmean
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart Dmean
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal Involuntary Movement Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression of Change‐Tardive Dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of internal anal sphincter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rectal perceptional threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total symptom severity score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: peak postoperative troponin C release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participation in mammogram screening
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of Th22 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: low density lipoprotein cholesterol (LDLC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: high density lipoprotein cholesterol (HDLC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in visual acuity (VA) of the amblyopic eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PR duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in sensory and motor conduction amplitudes and velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 24-hour urinary protein excretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: urinary TGF-beta1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: LRC probability at 4 years
Endpoint domain: Mortality/survival
Primary endpoint: Satisfactory opacification of the biliary system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean age of first use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean age of regular use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean age of first treatment contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation of antihypertensive treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Confirmed objective response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bronchial responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: KSS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Flank pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voiding pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma levels of tumor necrosis factor‐alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma levels of tumor necrosis factor receptor 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma levels of tumor necrosis factor receptor I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Support for smoke-free indoor policy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Support for outdoor smoking policies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak plasma CMV loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pregnancy loss rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: serum high density lipoprotein cholesterol (HDL‐C) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum triglyceride (TG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glucose tolerance test (GTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total: HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Freedom from recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Residual filling material left within the canals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required to remove root filling material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: increased risk of cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Lymphocyte count at 15 days posttransplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total number of NK cells at 3 and 6 months posttransplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: perceived support from caregivers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: attitudes toward sexual risk‐taking behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in IBS symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in gastrointestinal-specific anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in perceived knowledge of IBS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Emotional Exhaustion (EE)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depersonalization (DS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in esophageal temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total heat production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of severe COPD exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Mean amount of urokinase required for recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of heart attack
Endpoint domain: Mortality/survival
Primary endpoint: performance improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: scar colour improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scar height reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SjvO(2) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) increase at femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heparin dose response after protamine neutralisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 24-h weighted mean glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Likelihood of achieving LDA at week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody titers ≥ 1:10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LDL cholesterol lowering efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BPb concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of pro-inflammatory genes (RIPK2 and COX2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression of histone deacetylase genes (HDAC 2, 3 and 9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol recovery to the TSST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of VLUs healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of application of bandage systems
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: somnolence
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: partial pressure of oxygen in arterial blood/inspiratory oxygen supply index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FAA stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diabetes coherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: MR-proANP concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NT-proBNP concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Copeptin level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dopamine D₂ occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean increase in palatal length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved relationship functioning
Endpoint domain: Life impact
Endpoint subdomain: Relationship functioning
Primary endpoint: Fewer medical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total NHS cost
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Median spontaneous pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median pain relief score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (SF-36 scale)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of RCIN (serum creatinine increase ≥ 0.5 mg/dl within 48 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total number of depressive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmaceutical cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Daily cough score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LCQ score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: overall movement skill proficiency (gross motor quotient)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived athletic competence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total screen time (min·wk(‐1))
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Risk of death after ACS
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac troponin T concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative increase in red cell volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients able to donate 4 units of blood for autologous use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Preoperative hematocrit and reticulocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: sQUAL prediction accuracy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: End-test dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work and Social Adjustment Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: postoperative lactate dehydrogenase concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal concentration of thrombin-antithrombin complexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Survival function
Endpoint domain: Mortality/survival
Primary endpoint: Relapse rate to heavy drinking
Endpoint domain: Adverse events/effects
Primary endpoint: Domiciliary peak nasal flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nasal blockage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total nasal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes